COMP <GO>

ASND vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY

Ascendis Pharma A/S Ordinary Share (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ASND 3 — JNJ 10

▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ

LAST: $251.27 (-0.68%) • MKT CAP: $16.67B

balance-sheet

3.74

LAST: $273.20 (-0.73%) • MKT CAP: $662.49B

balance-sheet

5.59

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASND VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	ASND	JNJ	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	41.00%	67.90%	-26.90	JNJ	/gross-margins <GO>
Return on Invested Capital (ROIC)	9.90%	25.50%	-15.60	JNJ	/roic <GO>
EV/EBITDA & P/E Valuation	21.0x	18.5x	+2.50	JNJ	/valuation <GO>
Free Cash Flow Yield	2.21%	2.97%	-0.76	JNJ	/fcf-yield <GO>
Operating Margin	13.90%	34.70%	-20.80	JNJ	/operating-margins <GO>
Net Profit Margin	10.90%	28.50%	-17.60	JNJ	/net-margins <GO>
Revenue Growth (YoY)	12.10%	6.00%	+6.10	ASND	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE	3.74	5.59	-1.85	JNJ	/balance-sheet <GO>
Piotroski F-Score Quality	8/9	8/9	0.00	TIE	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	6.80%	7.20%	-0.40	ASND	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	64.8	60.4	+4.48	ASND	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	0.98	1.08	-0.10	JNJ	/macro-sensitivity <GO>
Forward P/E Multiple	27.6x	23.0x	+4.60	JNJ	/forward-pe <GO>
Enterprise Scale & Market Cap	$16.67B	$662.49B	-$645.82B	JNJ	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	ASND REV	JNJ REV	ASND GROSS %	JNJ GROSS %	ASND FCF	JNJ FCF
FY 2025	—	$94.19B	—	67.9%	—	$19.70B
FY 2024	—	$88.82B	—	69.1%	—	$19.84B
FY 2023	—	$85.16B	—	44.0%	—	$18.96B

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

ASND // BETA 0.98

JNJ // BETA 1.08